f0434
Polyneuropathies
Merck KGaA, Darmstadt, GermanyPhase 3Dormant
BB
64/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 49/ 100
- Competitive Position
- 95/ 100
Competitive context
3 Active assets in the Polyneuropathies cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
CYCLOHEXANEACETIC ACID, 1-(AMINOMETHYL)- Merck KGaA, Darmstadt, Germany | Phase 3 | B |
Acoramidis Eidos Therapeutics, a BridgeBio company | Phase 3 | B |
Nexiguran Ziclumeran Intellia Therapeutics | Phase 3 | B |
Capsaicin | Phase 2 | B |
Patisiran Austin Neuromuscular Center | Early Phase 1 | CC |
Allogeneic Adipose-Derived Mesenchymal Stem Cells | D |
Same molecule, other indications
f0434 is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →